Logo do repositório
 
Publicação

Guillain-Barré Syndrome After a SARS-CoV-2 Vaccine

datacite.subject.fosCiências Médicas
dc.contributor.authorOliveira, Ana Maria; Ramos, Patrícia Varela; Durão-Carvalho, Gonçalo; Almeida, Vânia; Gonçalves Pereira, João
dc.date.accessioned2025-06-02T15:49:21Z
dc.date.available2025-06-02T15:49:21Z
dc.date.issued2024
dc.description.abstractAbstract The worldwide mass vaccination campaign against COVID-19 has been the largest one ever undertaken. Although the short-term safety profile of the different vaccines has been well established, neuroinflammatory complications have been described, including rare cases of acute demyelinating inflammatory polyneuropathy. We report a 63-year-old man who presented to the emergency department with proximal muscle weakness and paresthesia. He had received the first dose of the AZD1222 SARS-CoV-2 vaccine (Oxford, AstraZeneca) two weeks before presentation. The diagnosis of Guillain-Barré syndrome (GBS) was confirmed by clinical features, cerebrospinal fluid analysis, and electromyography. On the second hospital day, progression to flaccid tetraplegia, cranial nerve involvement, and respiratory failure, requiring invasive mechanical ventilation, were noted, and he was admitted to the intensive care unit. Despite the prompt diagnosis and immunosuppressive treatment initiation, the patient was left with severe disability. Although the COVID-19 vaccination was generally safe and socially beneficial, individual adverse reactions, including neuroinflammatory severe complications, may occur.por
dc.identifier.doi10.7759/cureus.57705
dc.identifier.urihttp://hdl.handle.net/10400.26/57926
dc.language.isoeng
dc.peerreviewedyes
dc.relation.hasversionPMC11071625
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.titleGuillain-Barré Syndrome After a SARS-CoV-2 Vaccinepor
dc.typejournal article
dspace.entity.typePublication
oaire.citation.titleCureus
oaire.versionhttp://purl.org/coar/version/c_970fb48d4fbd8a85

Ficheiros

Principais
A mostrar 1 - 1 de 1
A carregar...
Miniatura
Nome:
SGB Case Report.pdf
Tamanho:
692.04 KB
Formato:
Adobe Portable Document Format
Licença
A mostrar 1 - 1 de 1
Miniatura indisponível
Nome:
license.txt
Tamanho:
1.85 KB
Formato:
Item-specific license agreed upon to submission
Descrição: